

METHOD FOR PRODUCING L-AMINO ACID USING METHYLOTROPH

BACKGROUND OF THE INVENTION

Field of the Invention

[0001] The present invention relates to a microbial engineering technique useful for production of amino acids and, more specifically to a method for producing L-lysine or L-arginine by fermentation. The present invention also relates to a microorganism useful for the production method.

Background Art

[0002] L-amino acids such as L-lysine, L-glutamic acid, L-threonine, L-leucine, L-isoleucine, L-valine and L-phenylalanine are industrially produced by fermentation using microorganisms belonging to the genus *Brevibacterium*, *Corynebacterium*, *Bacillus*, *Escherichia*, *Streptomyces*, *Pseudomonas*, *Arthrobacter*, *Serratia*, *Penicillium*, *Candida*, and the like. Bacterial strains isolated from nature or artificial mutants of these bacterial strains are often used in order to improve productivity of these microorganisms. Furthermore, various techniques have been disclosed for increasing L-amino acid production from these strains by enhancing the activity of L-amino acid biosynthetic enzymes using recombinant DNA techniques.

[0003] L-amino acid production has been considerably increased by breeding of microorganisms such as those mentioned above and the resulting improvements in the production methods. However, in order to respond to further increases in demand in the future, the development of methods which provide more efficient production of L-amino acids at a lower cost are clearly still necessary, and therefore, still represent a need in the art.

[0004] Methanol is a known fermentation raw material which is available in large amounts at a low cost. Methods for producing L-amino acids by fermentation using methanol are known and include methods using microorganisms that belong to the genus *Achromobacter* or *Pseudomonas* (Japanese

Patent Laid-open Publication (Kokai) No. 45-25273), *Protaminobacter* (Japanese Patent Publication (Kokoku) No. 49-125590), *Protaminobacter* or *Methanomonas* (Japanese Patent Laid-open Publication (Kokai) No. 50-25790), *Microcycylus* (Japanese Patent Laid-open Publication (Kokai) No. 52-18886), *Methylobacillus* (Japanese Patent Laid-open Publication (Kokai) No. 4-91793), *Bacillus* (Japanese Patent Laid-open Publication (Kokai) No. 3-505284) and so forth. The inventors of the present invention have developed methods for producing L-amino acids by breeding bacteria belonging to the genus *Methylophilus* and *Methylobacillus* using artificial mutagenesis and recombinant DNA techniques (International Publication WO00/61723; Japanese Patent Laid-open Publication (Kokai) No. 2001-120269).

[0005] In recent years, proteins have been identified that have a function of specifically secreting an L-amino acid to the outside of a cell or microorganism, as well as the genes which encode these proteins. In particular, Vrljic et al. have identified a gene involved in the secretion of L-lysine from a *Corynebacterium* bacterium to the outside of a cell (Molecular Microbiology 22:815-826 (1996)). This gene was designated as *lysE*, and it was reported that L-lysine producing ability of *Corynebacterium* bacteria could be improved by enhancing the expression of this gene in the bacteria (International Publication WO97/23597). It is also known that production of several kinds of L-amino acids can be improved by increasing expression amounts of amino acid secreting proteins in *Escherichia coli* (Japanese Patent Laid-open Publication No. 2000-189180). For example, it has been reported that production of cystine, cysteine, and so forth can be improved by enhancing the expression of ORF306 gene in *Escherichia coli* (European Patent Laid-open Publication No. 885962).

[0006] However, there have been no reports to date on improving the L-amino acid production by enhancing their secretion during fermentation of methanol-assimilating bacteria. Furthermore, no amino acid secretion gene that can exhibit secretion activity in methanol-assimilating bacteria has been reported.

SUMMARY OF THE INVENTION

[0007] An object of the present invention is to provide a method for efficiently producing L-lysine or L-arginine using methanol, which is abundantly and inexpensively available.

[0008] It is a further object of the present invention to provide a DNA encoding for a mutant of LysE protein, or a homologous protein thereof, of a coryneform bacterium, wherein the mutant, or homologous protein thereof, when introduced into a methanol-assimilating bacterium imparts resistance to a L-lysine analogue .

[0009] It is a further object of the present invention to provide a DNA as stated above, wherein the mutant is a protein defined as the following (A) or (B): (A) a protein which has the amino acid sequence of SEQ ID NO: 2 , whereby at least the glycine residue at position 56 is replaced by another amino acid, or (B) a protein which has the amino acid sequence of SEQ ID NO: 2 whereby at least the glycine residue at position 56 is replaced with another amino acid residue, and one or several amino acid residues at positions other than the 56th residue are substituted, deleted, inserted or added, and when said mutant is introduced into a methanol-assimilating bacterium, imparts resistance to a L-lysine analogue.

[0010] It is even a further object of the present invention to provide the DNA as stated above, wherein said DNA is selected from the group consisting of A) a DNA which has the nucleotide sequence of SEQ ID NO: 1, whereby a mutation results in replacement of at least the 56th glycine residue of the encoded protein with another amino acid residue, or B) a DNA which is hybridizable with the nucleotide sequence of SEQ ID NO: 1 under the stringent conditions, or a probe prepared from said nucleotide sequence, which when introduced into a methanol-assimilating bacterium, imparts resistance to L-lysine analogue.

[0011] It is even a further object of the present invention to provide the DNA as stated above, wherein the other amino acid residue is a serine residue.

[0012] It is even a further object of the present invention to provide the DNA as stated above,

wherein the L-lysine analogue is S-(2-aminoethyl)cysteine.

[0013] It is even a further object of the present invention to provide the DNA as stated above, wherein the methanol-assimilating bacterium is a bacterium belonging to the genus *Methylophilus* or *Methylobacillus*.

[0014] It is even a further object of the present invention to provide a bacterium belonging to the genus *Methylophilus* or *Methylobacillus*, into which the DNA as described above in an expressible form is introduced and which has L-lysine or L-arginine producing ability.

[0015] It is even a further object of the present invention to provide a method for producing L-lysine or L-arginine comprising the steps of A) culturing the bacterium as described above in a medium to produce and accumulate L-lysine or L-arginine in the culture, and B) collecting L-lysine or L-arginine from the culture.

[0016] It is even a further object of the present invention to provide the method as stated above, wherein the medium contains methanol as a main carbon source.

[0017] According to the present invention, the L-amino acid productivity of methanol-assimilating bacteria, especially productivity of L-lysine and L-arginine, can be improved.

BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Fig. 1 shows a map of a plasmid pRStac having the *tac* promoter and a plasmid pRSlysE, which was constructed by inserting the *lysE* gene into pRStac.

DETAILED DESCRIPTION OF THE INVENTION

[0019] The inventors of the present invention assiduously studied to achieve the above-referenced objects of the present invention. Initially, they found that when an L-amino acid, in particular, L-lysine or L-arginine, is produced using methanol-assimilating bacteria, in particular, bacteria belonging to the genus *Methylophilus* and *Methylobacillus*, the extracellular secretion process of these

L-amino acids was unsuccessful. Then, the inventors were able to successfully obtain genes which exhibited an activity for secreting amino acids, especially in these microorganisms, and thus found that amino acids could be efficiently produced by utilizing the thus-obtained genes.

[0020] The inventors of the present invention introduced the already known *lysE* gene from *Corynebacterium* bacterium into a methanol-assimilating bacterium, and examined its effect on the amino acid production. It was found that introduction of the *lysE* gene into a methanol-assimilating bacterium resulted in mutation or deletion, and thus *lysE* could not function. Proteins responsible for secretion typically need to be incorporated into the cell membrane in order to function, therefore, the protein and membrane conditions such as lipid composition must be suitable for each other. It was concluded that it would be difficult to express a heterologous membrane protein, such as LysE, so that the protein can function, and this conclusion was supported by the aforementioned result.

[0021] Therefore, the inventors of the present invention found a mutant gene that could function in a methanol-assimilating bacterium while researching the aforementioned L-amino acid secretion gene. Furthermore, they found a marked effect upon use of this mutant gene in amino acid production using a methanol-assimilating bacteria. They further advanced the research and successfully obtained a plurality of mutant genes that can function in methanol-assimilating bacteria.

[0022] Hereinafter, the present invention will be explained in detail.

DNA of the Present Invention

[0023] The DNA of the present invention encodes a mutant of the LysE protein, or a homologous protein of the LysE protein, derived from a coryneform bacterium, which can exhibit a function of the LysE protein when it is introduced into a methanol-assimilating bacterium.

[0024] The “function of the LysE protein” as used herein means at least one of the functions defined as follows (1 and/or 2):

[0025] (1) Function of imparting resistance to L-lysine analogue when expressed in a methanol-

assimilating bacterium upon introduction of the aforementioned DNA encoding the mutant.

[0026] The expression “imparting resistance to L-lysine analogue” to the bacterium as used herein means that upon introduction of the aforementioned DNA encoding the LysE mutant into the aforementioned methanol-assimilating bacterium, the bacterium is able to grow in the presence of a higher concentration of L-lysine analogues compared with bacteria which do not contain the DNA, for example, wild-type strains of the methanol-assimilating bacteria. For example, after culture on an agar medium containing an L-lysine analogue at a certain concentration for a certain period, if a transformant strain of the methanol-assimilating bacterium introduced with the aforementioned DNA forms colonies, but a non-transformant strain does not form colonies, the aforementioned transformant strain is imparted with resistance to the L-lysine analogue. Examples of the L-lysine analogue include S-(2-aminoethyl)cysteine.

[0027] (2) Function of enhancing extracellular secretion of one or both of L-lysine or L-arginine, when the aforementioned mutant is introduced into a methanol-assimilating bacterium

[0028] The expression of “enhancing extracellular secretion of one or both of L-lysine or L-arginine” as used herein means that, when a methanol-assimilating bacterium containing the DNA of the present invention is cultured, the amount of one or both of L-lysine or L-arginine secreted into a medium is increased compared with the methanol-assimilating bacterium which does not contain the DNA of the present invention. The enhancement of extracellular secretion of the L-amino acid is observed by an increased concentration of the L-amino acid accumulated in the medium during culture of a methanol-assimilating bacterium containing the DNA of the present invention compared with the methanol-assimilating bacterium not containing the DNA of the present invention, as a result of the introduction of the DNA. Furthermore, the enhancement of extracellular secretion of the L-amino acid can also be observed when a decreased intracellular L-amino acid concentration is detected upon introduction of the DNA of the present invention into a methanol-assimilating bacterium.

[0029] In the present invention, the methanol-assimilating bacterium, that is, methylotroph, means a bacterium which can grow by utilizing methanol as a major carbon source, and in which the function of the LysE protein is expressed when the DNA of the present invention is introduced. Specific examples include *Methylophilus* bacteria such as *Methylophilus methylotrophus* and *Methylobacillus* bacteria such as *Methylobacillus glycogenes* and *Methylobacillus flagellatum*.

[0030] Examples of *Methylophilus methylotrophus* include, but are not limited to the AS1 strain (NCIMB10515) and so forth. The *Methylophilus methylotrophus* AS1 strain (NCIMB10515) is available from the National Collections of Industrial and Marine Bacteria (Address: NCIMB Ltd., Torry Research Station, 135, Abbey Road, Aberdeen AB9 8DG, United Kingdom).

[0031] Examples of *Methylobacillus glycogenes* include, but are not limited to the T-11 strain (NCIMB 11375), ATCC 21276 strain, ATCC 21371 strain, ATR80 strain (described in Appl. Microbiol. Biotechnol., 42, pp.67-72 (1994)), A513 strain (described in Appl. Microbiol. Biotechnol., 42, pp.67-72 (1994)) and so forth. The *Methylobacillus glycogenes* NCIMB 11375 strain is available from the National Collections of Industrial and Marine Bacteria (Address: NCIMB Ltd., Torry Research Station, 135, Abbey Road, Aberdeen AB9 8DG, United Kingdom). Examples of *Methylobacillus flagellatum* include, but are not limited to the KT strain (described in Arch. Microbiol., 149, pp.441-446 (1988)) and so forth.

[0032] One embodiment of the DNA of the present invention is a DNA encoding for a protein which has the amino acid sequence of SEQ ID NO: 2, whereby at least the glycine residue at position 56 is replaced with another amino acid residue.

[0033] Furthermore, a more specific embodiment of the DNA of the present invention is a DNA encoding for a protein which has the amino acid sequence of SEQ ID NO: 2 and includes a mutation for any of the following:

[0034] (i) replacement of the glycine residue at position 56 in SEQ ID NO: 2 with another amino acid residue;

[0035] (ii) replacement of the glycine residue at position 56 in SEQ ID NO: 2 with another amino acid residue, and replacement of the alanine residue at position 55 in SEQ ID NO: 2 with another amino acid residue;

[0036] (iii) replacement of the glycine residue at position 56 in SEQ ID NO: 2 with another amino acid residue, and replacement of the aspartic acid residue at position 137 in SEQ ID NO: 2 with another amino acid residue.

[0037] Specific examples of the replacement at the 56th position include, but are not limited to replacement of the glycine residue with a serine residue. Specific examples of the replacement at the 55th position include, but are not limited to replacement of the alanine residue with a threonine residue. Specific examples of replacement at the 137th position include, but are not limited to replacement of the aspartic acid residue with a glycine residue.

[0038] More specific embodiments of the DNA of the present invention encoding proteins having the aforementioned replacements are DNAs designated as *lysE562*, *lysE564* and *lysE565* described herein in the examples. These are mutants of genes isolated from *Brevibacterium lactofermentum* as homologues of the *lysE* gene reported for *Corynebacterium* bacteria. Therefore, the DNA of the present invention is also referred to as “mutant *lysE*,” and the protein encoded by the DNA of the present invention as “mutant LysE,” for convenience.

[0039] As a DNA encoding for the LysE protein of coryneform bacteria, the nucleotide sequence of wild-type *lysE* of *Brevibacterium lactofermentum* is shown in SEQ ID NO: 1, and the amino acid sequence of the encoded protein is shown in SEQ ID NO: 2.

[0040] It was found that the glycine at the 56th position from the amino terminus is changed to serine in the amino acid sequence of the protein encoded by *lysE564*, as compared to the amino acid sequence of SEQ ID NO: 2 encoded by wild-type *lysE*. It was found that the glycine at the 56th position from the amino terminus is changed to serine and aspartic acid at the 137th position is changed to glycine in the amino acid sequence of the protein encoded by *lysE562*, as compared to the

amino acid sequence of SEQ ID NO: 2 encoded by wild-type *lysE*. It was also found that the glycine at the 56th position from the amino terminus is changed to serine, and the alanine at the 55th position is changed to threonine in the amino acid sequence of the protein encoded by *lysE565* as compared with the amino acid sequence encoded by wild-type *lysE*. The common mutation point was found to be the replacement of glycine with serine at the 56th position. It was determined that the change at this position was important, in particular, for production of a secretion carrier which has an activity of secretion of L-lysine in a methylotroph.

[0041] The DNA of the present invention may encode an amino acid sequence including substitution, deletion, insertion or addition of one or several amino acid residues at positions other than the 55th, 56th and 137th positions so long as the encoded mutant LysE has any of the aforementioned mutations and exhibits the function of the LysE protein in a methanol-assimilating bacterium. The term "several" as used herein varies depending on the positions of amino acid residues in the three-dimensional structure of the protein and the types of the amino acids. However, it preferably means between 2 to 10 amino acid residues, more preferably between 2 to 5, and most preferably between 2 to 3.

[0042] A DNA encoding for a protein substantially identical to the aforementioned mutant LysE can be obtained by modifying the nucleotide sequence of the mutant *lysE*. For example, site-directed mutagenesis can be employed so that substitution, deletion, insertion or addition of an amino acid residue or residues occurs at a specific site. Furthermore, a DNA modified as described above can also be obtained by conventionally-known mutation treatments. Examples of such mutation treatments include a method of treating the DNA before the mutation treatment *in vitro* with hydroxylamine or the like, a method of treating a microorganism, for example, an *Escherichia* bacterium, containing DNA before the mutation treatment with ultraviolet ray irradiation or a mutagenesis agent used in a usual mutation treatment such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) or nitrous acid, and so forth. These methods are described in Sambrook, J., Fritsch, E.F., and

Maniatis, T., "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989) and so forth.

[0043] A DNA encoding for a protein substantially identical to the mutant LysE can be obtained by expressing a DNA including any of the aforementioned mutations in a methanol-assimilating bacterium and examining the activity of the expression product.

[0044] In the present invention, the positions of the amino acid residues are not necessarily absolute positions in each LysE protein, but positions relative to the positions in the amino acid sequence of SEQ ID NO: 2. For example, when one amino acid residue is deleted on the N-terminus side of the 56th position in the amino acid sequence of SEQ ID NO: 2, the aforementioned 56th amino acid residue becomes the 55th amino acid residue from the N-terminus. In this case, since the 55th amino acid residue from the N-terminus is an amino acid residue corresponding to the 56th amino acid residue in SEQ ID NO: 2, it is the "56th" amino acid residue.

[0045] The DNA encoding LysE protein of coryneform bacterium or its homologue protein, i.e., the *lysE* gene or its homologous gene, may be obtained from any microorganism, so long as the microorganism has variants of genes that can express the L-lysine secretion activity in a methanol-assimilating bacterium. Specifically, examples of such microorganisms include, but are not limited to, coryneform bacteria such as *Corynebacterium glutamicum* and *Brevibacterium lactofermentum*, *Escherichia* bacteria such as *Escherichia coli*, *Pseudomonas* bacteria such as *Pseudomonas aeruginosa*, *Mycobacterium* bacteria such as *Mycobacterium tuberculosis* and so forth.

[0046] Examples of the homologous gene to *lysE* include a DNA encoding for a protein, which is hybridizable with a probe having the nucleotide sequence of SEQ ID NO: 1 or a part thereof under stringent conditions, and codes for a protein which exhibits the function of the LysE protein in a methanol-assimilating bacterium as a result of the aforementioned amino acid substitution. The aforementioned "stringent conditions" include a condition under which a so-called specific hybrid is formed, and a non-specific hybrid is not formed. It is difficult to clearly express this condition by

using any numerical value. However, for example, the stringent conditions include a condition whereby DNAs having high homology, for example, DNAs having homology of 80% or more, preferably 90% or more, more preferably 95% or more, are hybridized with each other, whereas DNAs having homology lower than the above do not hybridize with each other. Alternatively, the stringent conditions are exemplified by conditions whereby DNAs hybridize with each other at a salt concentration upon ordinary conditions of washing in Southern hybridization, i.e., 1 x SSC, 0.1% SDS, preferably 0.1 x SSC, 0.1% SDS, at 60°C.

[0047] A partial sequence of the nucleotide sequence of SEQ ID NO: 1 can also be used as the probe. Probes can be generated by PCR using oligonucleotides based on the nucleotide sequence of SEQ ID NO: 1 as primers, and a DNA fragment containing the nucleotide sequence of SEQ ID NO: 1 as a template. When a DNA fragment of about 300 bp is used as the probe, the washing conditions of hybridization can be, for example, 2 x SSC, 0.1% SDS at 50°C.

[0048] In order to enhance the mutant *lysE* gene expression in a methanol-assimilating bacterium such as *Methylophilus* bacteria or *Methylobacillus* bacteria, the gene fragment containing the mutant *lysE* gene can be ligated to a vector that functions in a methanol-assimilating bacterium, preferably a multi-copy type vector, to prepare recombinant DNA and used to transform a host such as a methanol-assimilating bacterium. Alternatively, the mutant *lysE* gene may be incorporated into a transposon and introduced into the chromosome. Furthermore, a promoter that induces potent transcription in a methanol-assimilating bacterium can be ligated to the upstream of the mutant *lysE* gene.

[0049] The reference WO97/23597 discloses *lysE*, and only shows the *lysE* gene of coryneform bacterium introduced into a coryneform bacterium. Furthermore, it only mentions L-lysine as the secreted amino acid, and discloses a novel protein secretion system, including LysE having a structure containing six transmembrane helixes. However, the inventors of the present invention confirmed that LysE derived from coryneform bacteria did not function at all in methanol-assimilating bacteria.

[0050] Furthermore, the obtained factor is a novel L-lysine secretion carrier that includes a

substitution mutation of an amino acid at a specific site, and such a factor cannot be inferred at all from the previous patent specifications concerning *lysE*.

Methanol-Assimilating Bacterium of the Present Invention

[0051] The methanol-assimilating bacterium of the present invention is a methanol-assimilating bacterium into which the aforementioned DNA of the present invention in an expressible form is introduced and which has L-lysine- or L-arginine- producing ability. The methanol-assimilating bacterium of the present invention can be obtained by introducing the DNA of the present invention into a methanol-assimilating bacterium having L-lysine- or L-arginine- producing ability. The methanol-assimilating bacterium of the present invention can also be obtained by imparting L-lysine- or L-arginine- producing ability to a methanol-assimilating bacterium introduced with the DNA of the present invention. Furthermore, the methanol-assimilating bacterium of the present invention may be a bacterium imparted with the L-lysine- or L-arginine- producing ability by introducing the DNA of the present invention in an expressible form.

[0052] Examples of the methanol-assimilating bacterium include, but are not limited to the aforementioned *Methylophilus* bacteria or *Methylobacillus* bacteria.

[0053] A methanol-assimilating bacterium having L-lysine- or L-arginine- producing ability can be obtained by imparting an L-lysine- or L-arginine- producing ability to a wild-type strain of a methanol-assimilating bacterium. Methods conventionally used for breeding of coryneform bacteria, *Escherichia* bacteria and so forth, can be used to impart the L-lysine- or L-arginine- producing ability. For example, such methods include, but are not limited to acquisition of auxotrophic mutant strains, analogue resistant strains or metabolic regulation mutant strains, creation of recombinant strains in which an L-lysine or L-arginine biosynthesis system enzyme is enhanced (see "Amino Acid Fermentation", the Japan Scientific Societies Press [Gakkai Shuppan Center], 1st Edition, published on May 30, 1986, pp.77 to 100) and so forth. Properties of auxotrophy, analogue resistance,

metabolic regulation mutation and so forth may be individually imparted or two or more may be imparted in combination when breeding L-lysine- or L-arginine- producing bacteria. The biosynthesis system enzyme may be individually enhanced or two or more of them may be enhanced in combination. Furthermore, the impartation of properties including auxotrophy, analogue resistance, metabolic regulation mutation and so forth may be combined with the enhancement of biosynthesis system enzyme.

[0054] For example, L-lysine-producing bacteria can be bred to be auxotrophic for L-homoserine or L-threonine and L-methionine (Japanese Patent Publication Nos. 48-28078 and 56-6499), or be auxotrophic for inositol or acetic acid (Japanese Patent Laid-open Nos. 55-9784 and 56-8692), or be resistant to oxalysine, lysine hydroxamate, S-(2-aminoethyl)-cysteine, γ -methyllysine, α -chlorocaprolactam, DL- α -amino- ϵ -caprolactam, α -amino-lauryllactam, aspartic acid analogue, a sulfa drug, quinoid or N-lauroylleucine.

[0055] L-arginine-producing bacteria can be bred to be resistant to a certain agent, for example, a sulfa drug, 2-thiazolealanine, α -amino- β -hydroxyvaleric acid or the like; to be auxotrophic for L-histidine, L-proline, L-threonine, L-isoleucine, L-methionine or L-tryptophan in addition to resistance to 2-thiazolealanine (Japanese Patent Laid-open No. 54-44096); to be resistant to ketomalonic acid, fluoromalonic acid or monofluoroacetic acid (Japanese Patent Laid-open No. 57-18989); to be resistant to argininol (Japanese Patent Laid-open No. 62-24075); to be resistant to X-guanidine (X represents a derivative of fatty acid or aliphatic chain, Japanese Patent Laid-open No. 2-186995); to be resistant to 5-azauracil, 6-azauracil, 2-thiouracil, 5-fluorouracil, 5-bromouracil, 5-azacytosine, 6-azacytosine and so forth; to be resistant to arginine hydroxamate and 2-thiouracil; to be resistant to arginine hydroxamate and 6-azauracil (see Japanese Patent Laid-open No. 57-150381); to be resistant to a histidine analogue or tryptophan analogue (see Japanese Patent Laid-open No. 52-114092); to be auxotrophic for at least one of methionine, histidine, threonine, proline, isoleucine, lysine, adenine, guanine and uracil (or uracil precursor) (see Japanese Patent Laid-open No. 52-99289); to be resistant

to arginine hydroxamate (see Japanese Patent Publication No. 51-6754); to be auxotrophic for succinic acid or resistant to a nucleic acid base analogue (see Japanese Patent Laid-open No. 58-9692); to be unable to metabolize arginine and to be resistant to an arginine antagonist and canavanine and to be auxotrophic for lysine (see Japanese Patent Laid-open No. 52-8729); to be resistant to arginine, arginine hydroxamate, homoarginine, D-arginine and canavanine, or resistant to arginine hydroxamate and 6-azauracil (see Japanese Patent Laid-open No. 53-143288); to be resistant to canavanine (see Japanese Patent Laid-open No. 53-3586) and so forth.

[0056] Hereinafter, methods for imparting or enhancing L-amino acid-producing ability by enhancing an L-amino acid biosynthetic enzyme gene are exemplified.

[0057] L-lysine-producing ability can be imparted by, for example, enhancing activities of dihydrodipicolinate synthase and aspartokinase. The activities of dihydrodipicolinate synthase and aspartokinase in a methanol-assimilating bacterium can be enhanced by transforming the methanol-assimilating bacterium host with a recombinant DNA, which has been prepared by ligating a gene fragment encoding dihydrodipicolinate synthase and a gene fragment encoding aspartokinase with a vector that functions in the methanol-assimilating bacterium, preferably a multiple copy type vector. The activities of dihydrodipicolinate synthase and aspartokinase are enhanced as a result of the increase in copy numbers of the genes encoding the enzymes in the transformant strain. Hereinafter, dihydrodipicolinate synthase, aspartokinase and aspartokinase III are also referred to as DDPS, AK and AKIII, respectively.

[0058] Any microorganism may provide the genes which encode DDPS and AK, so long as the chosen microorganism harbors genes which can express DDPS activity and AK activity in a methanol-assimilating bacterium. Such microorganisms may be wild-type strains or mutant strains derived therefrom. Specifically, examples of such microorganisms include, but are not limited to *E. coli* (*Escherichia coli*) K-12 strain, *Methylophilus methylotrophus* AS1 strain (NCIMB10515) and *Methylobacillus glycogenes* T-11 strain (NCIMB 11375) and so forth. These genes can be obtained

by PCR using primers synthesized based on the known nucleotide sequences of DDPS (*dapA*, Richaud, F. et al., J. Bacteriol., 297 (1986)) and AKIII (*lysC*, Cassan, M., Parsot, C., Cohen, G.N. and Patte, J.C., J. Biol. Chem., 261, 1052 (1986)) and using chromosomal DNA from a microorganism such as *E. coli* K-12 as a template. Specific examples include, but are not limited to *dapA* and *lysC* derived from *E. coli*, as explained herein.

[0059] Preferably, the DDPS and AK used in the present invention will not be subject to feedback inhibition by L-lysine. It is known that wild-type DDPS derived from *E. coli* is subject to feedback inhibition by L-lysine (see US Patents 5,661,012 and 6,040,160) and that wild-type AKIII derived from *E. coli* is subject to suppression and feedback inhibition by L-lysine. Therefore, *dapA* and *lysC* preferably encode for DDPS and AKIII, respectively, each of which contain a mutation that eliminates the feedback inhibition by L-lysine upon introduction into a methanol-assimilating bacterium. Hereinafter, DDPS which contains a mutation that eliminates the feedback inhibition by L-lysine may also be referred to as "mutant DDPS," and DNA encoding the mutant DDPS may also be referred to as "mutant *dapA*," or "*dapA**." AKIII derived from *E. coli* which contains a mutation that eliminates the feedback inhibition by L-lysine may also be referred to as "mutant AKIII," and DNA encoding the mutant AKIII may also be referred to as "mutant *lysC*."

[0060] However, it is not always necessary that DDPS and AK be mutated in the present invention. It is known that, for example, DDPS derived from *Corynebacterium* bacteria does not suffer feedback inhibition by L-lysine (see Korean Patent Publication No. 92-8382, US Patents 5,661,012 and 6,040,160).

[0061] A nucleotide sequence of wild-type *dapA* derived from *E. coli* is exemplified in SEQ ID NO: 3, and the amino acid sequence of wild-type DDPS encoded by this nucleotide sequence is exemplified in SEQ ID NO: 4.

[0062] The DNA encoding mutant DDPS that does not suffer feedback inhibition by L-lysine may be a DNA encoding DDPS having the amino acid sequence of SEQ ID NO: 4, including replacing

the histidine residue at position 118 of SEQ ID NO: 4 with a tyrosine residue. Furthermore, the DNA encoding mutant AKIII that does not suffer feedback inhibition by L-lysine may be a DNA encoding AKIII having the amino acid sequence including replacing the threonine at position 352 with an isoleucine residue (for the AKIII sequence, see US Patents 5,661,012 and 6,040,160).

[0063] The plasmid used for gene cloning may be any plasmid so long as it can replicate in microorganisms such as *Escherichia* bacteria. Specifically, examples of such bacteria include pBR322, pTWV228, pMW119, pUC19 and so forth.

[0064] Vectors that functions in *Methylophilus* bacteria include, for example, a plasmid that can autonomously replicate in *Methylophilus* bacteria. Specifically, examples include RSF1010, which is a broad host spectrum vector, and derivatives thereof, pAYC32 (Chistorerdov, A.Y., Tsygankov, Y.D. Plasmid, 16, 161-167 (1986)), pMFY42 (Gene, 44, 53 (1990)), pRP301, pTB70 (Nature, 287, 396, (1980)) and so forth.

[0065] Furthermore, examples of vectors that function in *Methylobacillus* bacteria include, for example, a plasmid that can autonomously replicate in *Methylobacillus* bacteria. Specific examples include RSF1010, which is a broad host spectrum vector, and derivatives thereof such as pMFY42 (Gene, 44, 53 (1990)).

[0066] To prepare a recombinant DNA via ligation of *dapA* and *lysC* to a vector that functions in a methanol-assimilating bacterium, the vector is digested with a restriction enzyme suitable for the ends of a DNA fragment containing *dapA* and *lysC*. The ligation is usually performed by using a ligase such as T4 DNA ligase. The genes *dapA* and *lysC* may be incorporated into separate vectors or the same vector.

[0067] A wide host range plasmid RSFD80 is known (WO95/16042), and may be used in the present invention as the plasmid having a mutant *dapA* encoding for a mutant DDPS and a mutant *lysC* encoding for a mutant AKIII. An *E. coli* JM109 strain transformed with this plasmid was designated as AJ12396, and deposited at National Institute of Bioscience of Advanced Industrial

Science and Technology on October 28, 1993, receiving an accession number of FERM P-13936. Then, it was transferred to an international deposit under the provisions of the Budapest Treaty on November 1, 1994 and received an accession number of FERM BP-4859. RSFD80 can be obtained from the AJ12396 strain by a known method.

[0068] RSFD80 contains a mutant *dapA*, wherein the nucleotide sequence of wild-type *dapA* shown in SEQ ID NO: 3 is changed at position 597 from C to T. The histidine residue at position 118 of the wild-type DDPS of Seq ID No. 4, which is encoded by the wild-type *dapA* of Seq ID No. 3, is changed to a tyrosine residue as a result of the above nucleotide change. Furthermore, RSFD80 contains a mutant *lysC*, wherein the nucleotide sequence of wild-type *lysC* is changed at position 1638 from C to T. This mutation results in the mutant AKIII, however the threonine at position 352 is changed to a isoleucine.

[0069] Any method can be used to introduce the recombinant DNA prepared as described above into a *Methylophilus* bacterium or *Methylobacillus* bacterium, so long as it provides sufficient transformation efficiency. For example, electroporation can be used (Canadian Journal of Microbiology, 43, 197 (1997)).

[0070] Enhancing the expression of a desired gene can be accomplished by introducing multiple copies of the gene on chromosomal DNA of a *Methylophilus* bacterium. Multiple copies of *dapA* and *lysC* may be introduced into the chromosomal DNA of a *Methylophilus* bacterium by homologous recombination. This can be performed by targeting a sequence present on chromosomal DNA in multiple copy number. A repetitive DNA or an inverted repeat present at the end of a transposable element can be used as the sequence present on chromosomal DNA in multiple copy number. Alternatively, as disclosed in Japanese Patent Laid-open No. 2-109985, multiple copies of the desired gene can be introduced into chromosomal DNA by incorporating them into a transposon and transferring it. In both of the methods, activity of the desired genes will be amplified as a result of increased copy numbers of desired genes in transformant strains.

[0071] Besides the above gene amplification methods, expression of the desired gene can be enhanced by replacing an expression control sequence, such as promoters of *dapA* and *lysC*, with stronger ones (see Japanese Patent Laid-open No. 1-215280). Examples of strong promoters, include lac promoter, trp promoter, trc promoter, *tac* promoter, PR promoter and PL promoter of lambda phage, tet promoter, amyE promoter, spac promoter and so forth. Use of these promoters enhances expression of the desired gene, and thus the activity of the desired gene product is amplified. Such gene expression enhancement methods can be combined with the gene amplification (increasing the copy number of the desired gene) methods described above.

[0072] Preparation of a recombinant DNA can be accomplished by ligating a gene fragment and a vector once the vector is digested with a restriction enzyme corresponding to the terminus of the gene fragment. Ligation is usually performed by ligase such as T4 DNA ligase. The usual methods well known to those with skill in the art can be used as methods for digestion, and include ligation of DNA, preparation of chromosomal DNA, PCR, preparation of plasmid DNA, transformation, design of oligonucleotides used as primers and so forth. Such methods are described in Sambrook, J., Fritsch, E.F., and Maniatis, T., "Molecular Cloning A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press (1989) and so forth.

[0073] In addition to the enhancement of DDPS and AK gene expression or activity, other enzymes involved in the L-lysine biosynthesis may also be enhanced. Such enzymes include diaminopimelate pathway enzymes such as dihydrodipicolinate reductase, diaminopimelate decarboxylase, diaminopimelate dehydrogenase (see WO96/40934 for all of the foregoing enzymes), phosphoenolpyruvate carboxylase (Japanese Patent Laid-open No. 60-87788), aspartate aminotransferase (Japanese Patent Publication No. 6-102028), diaminopimelate epimerase and aspartic acid semialdehyde dehydrogenase, aminoadipate pathway enzymes such as homoaconitate hydratase and so forth.

[0074] Aspartokinase, aspartic acid semialdehyde dehydrogenase, dihydrodipicolinate synthase,

dihydrodipicolinate reductase and diaminopimelate decarboxylase derived from *Methylophilus methylotrophus* are described in WO 00/61723.

[0075] Furthermore, the microorganisms of the present invention may have decreased activity of an enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway for L-lysine, or may be deficient in such an enzyme. Illustrative examples of the enzyme that catalyzes a reaction for generating a compound other than L-lysine by branching off from the biosynthetic pathway for L-lysine include homoserine dehydrogenase (see WO95/23864).

[0076] The aforementioned techniques for enhancing activities of enzymes involved in the L-lysine biosynthesis can be similarly used for L-arginine.

[0077] L-arginine-producing ability can be improved by enhancing acetylornithine deacetylase activity, N-acetylglutamic acid-g-semialdehyde dehydrogenase activity, N-acetyl glutamokinase activity and argininosuccinase activity (see Japanese Patent Publication No. 5-23750).

[0078] L-arginine-producing ability can also be improved by enhancing activity of glutamate dehydrogenase (EP 1 057 893 A1), argininosuccinate synthase (EP0 999 267 A1), carbamoyl phosphate synthetase (EP1 026 247 A1) or N-acetylglutamate synthase (see Japanese Patent Laid-open No. 57-5693) or by disrupting the gene encoding an arginine repressor (*argR*).

Production of L-lysine or L-arginine

[0079] L-lysine or L-arginine can be produced by culturing a methanol-assimilating bacterium, such as *Methylophilus* bacteria or *Methylobacillus* bacteria, having L-lysine- or L-arginine- producing ability. L-lysine or L-arginine can be obtained as described above from the medium upon production and accumulation. L-lysine or L-arginine can then be collected from the culture.

[0080] The microorganism used in the present invention can be cultured by a method typically used in culture of methanol-assimilating microorganisms. Either a natural medium or synthetic

medium may be used as the medium in the present invention, so long as it contains a carbon source, a nitrogen source, inorganic ions and other organic trace amount components as required.

[0081] If methanol is used as a main carbon source, L-lysine or L-arginine can be produced at a low cost. If used as the main carbon source, methanol is added to a medium at a concentration of between 0.001 to 30%. As the nitrogen source, ammonium sulfate and so forth are added to the medium. In addition to these, trace-amount components such as potassium phosphate, sodium phosphate, magnesium sulfate, ferrous sulfate and manganese sulfate can be added in small amounts.

[0082] The culture is usually performed under aerobic conditions by shaking or aeration agitation while the pH is maintained between 5 and 9, and the temperature is maintained between 20 to 45°C, and it is typically complete within 24 to 120 hours.

[0083] L-lysine or L-arginine can usually be collected from the culture by a combination of an ion exchange resin method, precipitation method and other known methods.

Examples

[0084] Hereinafter, the present invention will be explained more specifically with reference to the preferred embodiments, given only by way of example.

[0085] Reagents produced by Wako Pure Chemical Industries or Nakarai Tesque were used unless otherwise specified. The compositions of media used in the examples are shown below. As for all the media, pH was adjusted with NaOH, KOH or HCl.

LB medium:

Bacto trypton (Difco)	10 g/L
Yeast extract (Difco)	5 g/L
NaCl	10 g/L

pH 7.0

Steam sterilization was performed at 120°C for 20 minutes

LB agar medium:

LB medium

Bacto agar 15 g/L

Steam sterilization was performed at 120°C for 20 minutes

SEII medium:

K ₂ HPO ₄	1.9 g/L
NaH ₂ PO ₄	1.56 g/L
MgSO ₄ •7H ₂ O	0.2 g/L
(NH ₄) ₂ SO ₄	5 g/L
CuSO ₄ •5H ₂ O	5 µg/L
MnSO ₄ •5H ₂ O	25 µg/L
ZnSO ₄ •7H ₂ O	23 µg/L
CaCl ₂ •2H ₂ O	72 mg/L
FeCl ₃ •6H ₂ O	9.7 mg/L
CaCO ₃ (Kanto Kagaku)	30 g/L
Methanol	2% (v/v)

pH 7.0

The components other than methanol were subjected to steam sterilization at 121°C for 15 minutes, and methanol was added after the medium was sufficiently cooled

SEII agar medium:

K ₂ HPO ₄	1.9 g/L
NaH ₂ PO ₄	1.56 g/L
MgSO ₄ •7H ₂ O	0.2 g/L
(NH ₄) ₂ SO ₄	5 g/L
CuSO ₄ •5H ₂ O	5 µg/L
MnSO ₄ •5H ₂ O	25 µg/L
ZnSO ₄ •7H ₂ O	23 µg/L
CaCl ₂ •2H ₂ O	72 mg/L
FeCl ₃ •6H ₂ O	9.7 mg/L
Methanol	0.5% (v/v)

pH 7.0

Bacto agar (Difco) 15 g/L

The components other than methanol were subjected to steam sterilization at 121°C for 15 minutes, and methanol was added after the medium was sufficiently cooled

Example 1

Construction of mutant *lysE* gene library

[0086] First, the *lysE* gene, a homologous gene of the gene enhancing the secretion of L-lysine known for *Corynebacterium* bacteria, was cloned from a *Brevibacterium* bacterium, and expression of the gene was attempted in a *Methylophilus* bacterium.

(1) Construction of pRSlysE

[0087] In order to introduce *lysE* into a *Methylophilus* bacterium, a known plasmid pRS (see International Patent Publication in Japanese (Kohyo) No. 3-501682) was used to construct a plasmid pRSlysE for expression of *lysE*. pRS is a plasmid having the vector segment of the pVIC40 plasmid (International Patent Publication WO90/04636, International Patent Publication in Japanese No. 3-501682) and obtained from pVIC40 by deleting a DNA region encoding the threonine operon contained in the plasmid. The plasmid pVIC40 is derived from a broad host spectrum vector plasmid pAYC32 (Chistorerdov, A. Y., Tsygankov, Y.D., Plasmid, 1986, 16, 161-167), which is a derivative of RSF1010.

[0088] Specifically, pRS was constructed as follows. The pVIC40 plasmid was digested with *EcoRI* and added with a phenol/chloroform solution and mixed with it to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected, and DNAs were collected by ethanol precipitation and separated on 0.8% agarose gel. A DNA fragment of about 8 kilobase pairs (hereinafter, "kbp") containing the vector side was collected by using EASY TRAP Ver. 2 (DNA collection kit, Takara Shuzo). The vector region fragment of the pVIC40 plasmid prepared as described above was self-ligated by using DNA Ligation Kit Ver. 2 (Takara Shuzo). This ligation reaction solution was used to transform *Escherichia coli* (*E. coli* JM109 competent cells, Takara Shuzo). The cells were applied on the LB agar medium containing 20 mg/L of streptomycin and incubated overnight at 37°C. The colonies that appeared on the agar medium were each inoculated

to the LB liquid medium containing 20 mg/L of streptomycin and cultured at 37°C for 8 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkaline SDS method, and structure of each plasmid was confirmed by digestion with restriction enzymes to obtain pRS.

[0089] Then, a plasmid pRStac having the *tac* promoter was constructed from pRS according to the scheme shown in Fig. 1. The pRStac plasmid was constructed as follows. The pRS vector was digested with restriction enzymes EcoRI and PstI, and added to a phenol/chloroform solution and mixed to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected, and DNAs were collected by ethanol precipitation and separated on 0.8% agarose gel. A DNA fragment of 8 kilobase pairs (henceforth abbreviated as “kbp”) was collected by using EASY TRAP Ver. 2 (DNA collection kit, Takara Shuzo). On the other hand, the *tac* promoter region was amplified by PCR using the pKK223-3 plasmid (expression vector, Pharmacia) as a template and the primers shown in SEQ ID NOS: 7 and 8 (a cycle consisting of denaturation at 94°C for 20 seconds, annealing at 55°C for 30 seconds and extension reaction at 72°C for 60 seconds was repeated for 30 cycles). Pyrobest DNA polymerase (Takara Shuzo) was used for PCR. The DNA fragment containing the amplified *tac* promoter was purified by using PCR prep (Promega) and then digested at the restriction enzyme sites preliminarily designed in the primers, i.e., at EcoRI and EcoT22I sites. Then, the reaction mixture was added to a phenol/chloroform solution and mixed to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected and DNAs were collected by ethanol precipitation and separated on 0.8% agarose gel. A DNA fragment of about 0.15 kbp was collected by using EASY TRAP Ver. 2.

[0090] The digestion products of the pRS vector and the *tac* promoter region fragment prepared as described above were ligated by using DNA Ligation Kit Ver. 2 (Takara Shuzo). This ligation reaction solution was used to transform *Escherichia coli* (*E. coli* JM109 competent cells, Takara Shuzo). The cells were plated on LB agar medium containing 20 mg/L of streptomycin and incubated overnight at 37°C. The colonies that appeared on the agar medium were each inoculated

into LB liquid medium containing 20 mg/L of streptomycin and cultured at 37°C for 8 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkali-SDS method and structure of each plasmid was confirmed by digestion with restriction enzymes to obtain pRStac. A plasmid in which the transcription directions of the streptomycin resistance gene on the pRS vector and the *tac* promoter were identical to each other was selected as pRStac.

[0091] pRStac obtained as described above was digested with Sse8387I (Takara Shuzo) and SspI (New England Biolabs), added to a phenol/chloroform solution and mixed to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected and DNAs were collected by ethanol precipitation and separated on 0.8% agarose gel to obtain a DNA fragment of about 9.0 kbp.

[0092] The *lysE* gene fragment was also amplified by PCR using chromosome extracted from the *Brevibacterium lactofermentum* 2256 strain (ATCC13869) as a template and the primers shown in SEQ ID NOS: 9 and 10 (denaturation at 94°C for 20 seconds, annealing at 55°C for 30 seconds and extension reaction at 72°C for 90 seconds). Pyrobest DNA polymerase (Takara Shuzo) was used for PCR. At this time, so that expression of the *lysE* gene is possible in a *Methylophilus* bacterium, the primers were designed so that nucleotides located 9-15 bp from the translation initiation codon of the *lysE* gene were replaced with a sequence that is known to function in a *Methylophilus* bacterium (Wyborn, N.R., Mills, J., Williamis, S.G and Jones, C.W., Eur. J. Biochem., 240, 314-322 (1996)). The obtained fragment was purified by using PCR prep (Promega) and then digested with Sse8387I and SspI. The reaction mixture was added to a phenol/chloroform solution and mixed to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected and DNAs were collected by ethanol precipitation and further collected from 0.8% agarose gel.

[0093] The digestion products of the pRStac vector and the *lysE* gene region fragment prepared as described above were ligated by using DNA Ligation Kit Ver. 2 (Takara Shuzo). This ligation reaction solution was used to transform *Escherichia coli* (*E. coli* JM109 competent cells, Takara Shuzo). The cells were plated on LB agar medium containing 20 mg/L of streptomycin and

incubated overnight at 37°C. The colonies that appeared on the agar medium were each inoculated into LB liquid medium containing 20 mg/L of streptomycin and cultured at 37°C for 8 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkali-SDS method and the structure of each plasmid was confirmed by digestion with restriction enzymes and determination of nucleotide sequence to obtain pRSlysE (Fig. 1). In pRSlysE, the *lysE* gene was positioned so that its transcription direction should be the same as that of the *tac* promoter.

(2) Introduction of pRSlysE into *Methylophilus* bacterium

[0094] pRSlysE obtained as described above was introduced into *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation (Canadian Journal of Microbiology, 43, 197 (1997)). In addition, pRS was also introduced into the AS1 strain as a control in the same manner as that for pRSlysE. As a result, several thousands of colonies were obtained per 1 µg of DNA with pRS used as a control, whereas only several colonies were obtained with pRSlysE.

[0095] When plasmids were extracted from transformant strains estimated to be introduced with pRSlysE and their nucleotide sequences were investigated, a spontaneous mutation was introduced in a region encoding *lysE* for all the investigated plasmids, and in some cases, a nonsense mutation was introduced as the mutation, by which a codon encoding an amino acid was replaced with a stop codon that terminated the translation. Furthermore, in the other plasmid, deletion of *lysE* gene was observed. It was considered that the function of *lysE* carried by such plasmids should be lost.

[0096] As described above, the introduction frequency of pRSlysE carrying the full length *lysE* gene into *Methylophilus methylotrophus* was extremely low, and only plasmids having a *lysE* mutant gene containing a mutation that eliminated the function could be introduced. Considering these facts in combination, it was estimated that the introduction of the *lysE* gene into *Methylophilus methylotrophus* was a lethal effect. This indicates that the *lysE* gene cannot universally function for the secretion of L-lysine in heterogenous bacteria.

[0097] The *Methylophilus methylotrophus* AS1 strain harboring pRSlysE introduced with a mutation was applied to an SEII plate containing 50 mg/L of streptomycin and cultured overnight at 37°C. Then, the cells from about 10 cm² of the medium surface were scraped, inoculated into SEII production medium (20 ml) containing 50 mg/L of streptomycin, and cultured at 37°C for 34 hours with shaking. After completion of the culture, the cells were removed by centrifugation and the L-lysine concentration in the culture supernatant was determined by using an amino acid analyzer (Nihon Bunko, high speed liquid chromatography). As a result, substantially no strain was obtained in which secretion of L-lysine was enhanced in spite of introduction of the mutant *lysE* gene.

[0098] As described above, the introduction of the already known *lysE* gene derived from *Corynebacterium* bacteria into methanol-assimilating bacteria results in a lethal effect. In the strains having a *lysE* gene introduced in only a small number, the introduced *lysE* gene suffered from mutation or deficiency, and *lysE* could not function. Since proteins responsible for secretion of amino acids function only when incorporated into a cell membrane, the protein and membrane conditions such as lipid composition must be mutually suitable. Therefore, it was considered difficult to express a membrane protein derived from an heterologous organism in such a way that its function was maintained. Accordingly, it was estimated that, if an artificial mutation introduction method was used by which more mutations can be positively introduced than natural mutations, a mutant *lysE* having L-lysine secretion ability could be successfully obtained from such mutants. Based on this concept, a mutant *lysE* library was constructed by using a mutation introduction method using hydroxylamine as described herein.

[0099] Furthermore, the inventors of the present invention considered that if a mutant *lysE* gene exhibiting L-lysine secretion activity in a methanol-assimilating bacterium was introduced into a methanol-assimilating bacterium, the degree of resistance to AEC (S-(2-aminoethyl)cysteine), an analogue compound of L-lysine, might be increased. Based on this concept, a screening system described herein was developed. First, the construction of the mutant *lysE* library will be described

in detail.

(3) Mutation treatment of pRSlysE plasmid

[0100] The *E. coli* JM109 strain harboring the pRSlysE plasmid carrying wild-type *lysE* (available from Takara Shuzo) was inoculated to the LB liquid medium containing 20 mg/L of streptomycin and cultured at 37°C for 8 hours with shaking. Each plasmid DNA was extracted from each culture broth by the alkaline SDS method.

[0101] Subsequently, a mutation was introduced into the prepared pRSlysE by an *in vitro* mutation method using hydroxylamine. That is, a solution containing 250 mM potassium phosphate buffer adjusted to pH 6.0, 400 mM hydroxylamine solution adjusted to pH 6.0, each as a final concentration, and 2 µg of pRSlysE plasmid and made 200 µl water was prepared and incubated at 75°C for 2 hours or 3 hours. Subsequently, the pRSlysE plasmid was collected from this solution by using EASY TRAP Ver. 2 (DNA collection kit, Takara Shuzo). Plasmids reacted with hydroxylamine for 2 hours and plasmids reacted with hydroxylamine for 3 hours were mixed to obtain an aggregate of pRSlysE plasmids introduced with mutations at various rates.

[0102] The aggregate of mutant pRSlysE plasmids obtained as described above, which were estimated to be introduced with mutations at various positions, were amplified, and *Escherichia coli* (*E. coli* JM109 competent cells, Takara Shuzo) were transformed with this plasmid aggregate, applied on the LB agar medium containing 20 mg/L of streptomycin and incubated overnight at 37°C to construct a library in *Escherichia coli*. All the colonies that appeared on the agar medium were scraped, inoculated to the LB liquid medium containing 20 mg/L of streptomycin and cultured at 37°C for 8 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkaline SDS method and used as a mutant pRSlysE plasmid library.

Introduction of mutant pRSlysE plasmid into *Methylophilus* bacterium and L-amino acid production

(1) Screening for functional type *lysE* from library of *lysE* introduced with artificial mutation

[0103] The mutant pRSlysE plasmid library obtained as described above was introduced into the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation (Canadian Journal of Microbiology, 43, 197 (1997)). As a control, wild-type pRSlysE was introduced into the AS1 strain. As a result, with pRSlysE used as a control, the previous examination result was reproduced, and only several colonies were obtained per 1 µg of DNA. On the other hand, with the mutant pRSlysE plasmid library, several hundreds to several thousands of colonies could be obtained. The examinations so far have shown that, in almost all of the several colonies that appeared when wild-type pRSlysE was introduced, *lysE* lost the function due to the introduction of natural mutation. That is, the introduction frequency of pRSlysE carrying the full length *lysE* gene into *Methylophilus methylotrophus* was extremely low, and only plasmids having a mutant *lysE* gene containing a mutation that eliminated the function could be introduced. Considering these facts together, it was estimated that introduction of the *lysE* gene into *Methylophilus methylotrophus* would result in a lethal effect. On the other hand, since colonies far more than the above appeared when the mutant pRSlysE plasmid library was introduced, mutation introduction by hydroxylamine treatment was attained at a high efficiency.

[0104] As described above, the mutant *lysE* library could be obtained as a mutant pRSlysE plasmid library. Then, a screening system was developed for obtaining functional-type *lysE*, which expresses an activity for secreting L-lysine extracellularly.

[0105] The *Methylophilus methylotrophus* AS1 strain containing the mutant pRSlysE plasmid library obtained as described above was suitably diluted so that several hundreds of colonies per plate should appear, applied on the SEII agar medium containing 50 mg/L of streptomycin and 3 g/L of L-threonine and incubated at 37°C for 48 hours. The colonies that appeared were replicated on the SEII agar medium containing 3 g/L of L-threonine and 0, 5, 7 or 10 g/L of AEC. When the colonies were replicated on a plate that did not contain AEC, the numbers of colonies that appeared on the

original plate and the replicated plate after the replication were the same. However, when the colonies were replicated on the plate containing AEC, the number of colonies that appeared on the replicated plate markedly decreased as compared with that of the original plate. The colonies formed on the replicated plate containing AEC at each concentration were transferred to a new SEII agar medium containing AEC and cultured, and acquisition of AEC resistance was confirmed based on the observation that a single colony could be formed on the same medium. From such strains, 100 strains were randomly selected and subjected to further screening.

(2) L-amino acid production by strain introduced with mutant pRSlysE plasmid

[0106] Among the *Methylophilus methylotrophus* AS1 strains harboring a mutant pRSlysE estimated to be introduced with a mutation and to impart AEC resistance to a host, 100 strains were applied to an SEII plate containing 50 mg/L of streptomycin and cultured overnight at 37°C. Then, the cells on about 10 cm² of the medium surface were scraped, inoculated to an SEII production medium (20 ml) containing 50 mg/L of streptomycin and cultured at 37°C for 48 hours with shaking. After completion of the culture, the cells were removed by centrifugation, and L-amino acids contained in the culture supernatant were isolated by thin layer chromatography and roughly quantified by a method utilizing detection with ninhydrin. As a result, it was found that L-lysine and L-arginine were extracellularly secreted at various concentrations. These 100 strains were roughly classified into 5 groups based on their patterns.

[0107] One typical strain was selected from each of these 5 groups, and the plasmids contained in these strains were designated as pRSlysE561, pRSlysE562, pRSlysE563, pRSlysE564 and pRSlysE565. These plasmids were purified, and the nucleotide sequences of their *lysE* regions were analyzed. As a result, it was found that pRSlysE562 and pRSlysE563, and pRSlysE561 and pRSlysE564 had completely identical sequences. Therefore, pRSlysE562, pRSlysE564 and pRSlysE565 were examined thereafter.

[0108] The nucleotide sequences of the regions encoding for the LysE protein in pRSlysE562, pRSlysE564 and pRSlysE565 were analyzed. As a result, it was found that *lysE564* included substitution at the 166th position of A (adenine) for G (guanine) in the DNA sequence of wild-type *lysE* shown in SEQ ID NO: 1. As a result, Ser (serine) was substituted for Gly (glycine) at the 56th position in the amino acid sequence of wild-type *lysE* shown in SEQ ID NO: 2. It was also found that *lysE562* included substitutions of A (adenine) for G (guanine) at the 166th position, and A (adenine) for G (guanine) at the 410th position in the DNA sequence of wild-type *lysE* shown in SEQ ID NO: 1. As a result, Ser (serine) was substituted for Gly (glycine) at the 56th position and Gly (glycine) was substituted for Asp (aspartic acid) at the 137th position in the amino acid sequence of wild-type *lysE* shown in SEQ ID NO: 2. It was further found that *lysE565* included substitutions of A (adenine) for G (guanine) at the 166th position and A (adenine) for G (guanine) at the 163rd position in the DNA sequence of wild-type *lysE* shown in SEQ ID NO: 1. As a result, Ser (serine) was substituted for Gly (glycine) at the 56th position and Thr (threonine) was substituted for Ala (alanine) 55th position in the amino acid sequence of wild-type *lysE* shown in SEQ ID NO: 2. When pRSlysE562, pRSlysE564 and pRSlysE565 were introduced into the AS1 strains again, these plasmids could be introduced at almost the same frequency as pRS. The plasmid-introduced strains were cultured by the same method as described above, and concentrations of L-lysine and L-arginine in the culture supernatants were quantified by using an amino acid analyzer (Nihon Bunko, high-performance liquid chromatography). The measurement results are shown in Table 1.

Table 1

Bacterial strain	L-lysine production amount (g/L)	L-arginine production amount (g/L)
AS1/pRS	0.01	<0.010
AS1/pRSlysE562	0.19	0.210

AS1/pRSlysE564	0.20	0.240
AS1/pRSlysE565	0.13	0.150

[0109] From the above results, it was found that pRSlysE562, pRSlysE564 and pRSlysE565 had activity for significantly increasing secretion of L-lysine and L-arginine. Furthermore, even when pRSlysE562, pRSlysE564 and pRSlysE565 were reintroduced into the AS1 strains, activity for increasing secretion L-lysine and L-arginine was maintained. Thus, it was demonstrated that the mutation of the AEC resistance-acquired strain was not introduced into the host, but into the plasmid.

[0110] The common mutation introduced into pRSlysE562, pRSlysE564 and pRSlysE565 was substitution of Ser (serine) for Gly (glycine) at the 56th position in the amino acid sequence of wild-type *lysE* shown in SEQ ID NO: 2. The *E. coli* JM109 strain transformed with pRSlysE564 having only this common mutation was designated AJ110086. This strain was deposited at International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology on September 26, 2002 as an international deposit under the provisions of the Budapest Treaty and received an accession number of FERM BP-8196.

[0111] The *lysE562* and *lysE565* genes can be readily obtained from *lysE564* by methods well known to those skilled in the art. Specifically, the *lysE562* gene can be obtained by incorporating a fragment of the region encoding for *lysE564* obtained from pRSlysE564 into, for example, pSELECTTM-1, a vector for site-directed mutation introduction produced by Promega, and introducing a site-directed mutation using Altered Sites™, a site-directed mutation introduction kit produced by Promega, to substitute G (guanine) for A (adenine) at the 410th position in SEQ ID NO: 1. In the above procedure, for example, the synthetic oligonucleotide of SEQ ID NO: 5 can be used as a primer. The 20th nucleotide in SEQ ID NO: 5 is subject to nucleotide substitution in the wild-type *lysE* gene. Similarly, the *lysE565* gene can be obtained by substituting A (adenine) for G (guanine) at the 166th position in SEQ ID NO: 1. For the mutation introduction, for example, the synthetic

oligonucleotide of SEQ ID NO: 6 can be used. The 16th and 19th nucleotides in SEQ ID NO: 6 are subject to nucleotide substitution in the wild-type *lysE* gene.

Example 2: Introduction of L-lysine biosynthesis enzyme gene and *lysE562*, *lysE564* or *lysE565* gene into *Methylophilus methylotrophus*

[0112] Since it was found that the extracellular secretion of L-lysine was enhanced by the introduction of the *lysE562*, *lysE564* or *lysE565* genes, an L-lysine biosynthesis was enhanced in a strain introduced with the *lysE562*, *lysE564* or *lysE565* gene to attempt further improvement of the productivity.

(1) Construction of plasmid pRSdapA having *dapA** gene

[0113] A plasmid having a gene encoding dihydrodipicolinate synthase that did not suffer feedback inhibition by L-lysine (*dapA**) as an L-lysine biosynthesis system enzyme gene was prepared.

[0114] pRStac prepared in Example 1 was digested with *Sse8387I* and *XbaI* and added to a phenol/chloroform solution and mixed to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected, and DNAs were collected by ethanol precipitation and separated on a 0.8% agarose gel to collect a DNA fragment of about 9 kbp.

[0115] The *dapA** gene fragment was amplified by PCR using the known plasmid RSFD80 (see WO90/16042) containing that gene as a template and the primers shown in SEQ ID NOS: 11 and 12 (denaturation at 94°C for 20 seconds, annealing at 55°C for 30 seconds and extension reaction at 72°C for 60 seconds). Pyrobest DNA polymerase (Takara Shuzo) was used for PCR. The resulting *dapA** fragment was purified by using PCR prep (Promega) and then digested with restriction enzymes *Sse8387I* and *XbaI*. The reaction mixture was added to a phenol/chloroform solution and mixed to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected, and DNAs were collected by ethanol precipitation and separated on a 0.8% agarose gel to collect a DNA fragment of about 0.1 kbp.

[0116] The digestion products of the pRStac vector and the *dapA** gene region fragment prepared as described above were ligated by using DNA Ligation Kit Ver. 2 (Takara Shuzo). This ligation reaction solution was used to transform *Escherichia coli* (*E. coli* JM109 competent cells, Takara Shuzo). The cells were plated on LB agar medium containing 20 mg/L of streptomycin and incubated overnight at 37°C. The colonies that appeared on the agar medium were each inoculated into LB liquid medium containing 20 mg/L of streptomycin and cultured at 37°C for 8 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkali-SDS method and the structure of each plasmid was confirmed by digestion with restriction enzymes and determination of the nucleotide sequence to obtain a pRSdapA plasmid. In pRSdapA plasmid, the *dapA** gene was positioned so that its transcription direction should be the same as that of the *tac* promoter.

(2) Construction of plasmid having *dapA** gene and any of *lysE562*, *lysE564* or *lysE565* gene

[0117] In order to evaluate the effect of combining any of *lysE562*, *lysE564* or *lysE565* with *dapA**, plasmids pRSlysE562, pRSlysE564 and pRSlysE565 were constructed by insertion of the *dapA** gene. pRSlysE562, *lysE564* and *lysE565* prepared in Example 1 were digested with a restriction enzyme *SapI* and blunt-ended by using DNA Blunting Kit (Takara Shuzo). Furthermore, a pRSdapA plasmid was digested with restriction enzymes *EcoRI* and *SapI*, and a fragment of about 1 kbp having the *tac* promoter and the *dapA** region was separated on a 0.8% agarose gel and collected by using EASY TRAP Ver. 2 (Takara Shuzo). This fragment was blunt-ended as described above and ligated to each of the digestion products of the aforementioned pRSlysE562, *lysE564* and *lysE565* by using DNA Ligation Kit Ver. 2 (Takara Shuzo).

[0118] *Escherichia coli* (*E. coli* JM109 competent cells, Takara Shuzo) was transformed with each of the aforementioned ligation reaction solutions, applied on the LB agar medium containing 20 mg/L of streptomycin and incubated overnight at 37°C. The colonies that appeared on the agar medium were inoculated into the LB liquid medium containing 20 mg/L of streptomycin and cultured at 37°C

for 8 hours with shaking. The plasmid DNA was extracted from each culture broth by the alkaline SDS method, and structure thereof was confirmed by digestion with restriction enzymes and determination of the nucleotide sequence to obtain pRSlysE562dapA, pRSlysE564dapA and pRSlysE565dapA plasmids. In these plasmids, the genes were positioned so that the transcription directions of *lysE562*, *lysE564* and *lysE565* should be opposite to that of *dapA*^{*}.

[0119] When the pRSlysE562dapA, pRSlysE564dapA and pRSlysE565dapA plasmids obtained by the aforementioned method were each introduced into the *Methylophilus methylotrophus* AS1 strain (NCIMB10515) by electroporation, transformant strains were obtained with pRSlysE562dapA and pRSlysE564dapA, whereas no transformant strain was obtained with pRSlysE565dapA. This may be because stability of the plasmid decreased in the AS1 strain.

(3) Production of L-lysine by *Methylophilus* bacteria harboring *lysE562* or *lysE564* and *dapA*^{*}

[0120] The AS1 strains introduced with pRSlysE562dapA or pRSlysE564dapA obtained as described above or pRSlysEdapA as a control were each applied to an SEII plate containing 20 mg/L of streptomycin and cultured overnight at 37°C, and the cells on 0.3 cm² of the medium surface were scraped, inoculated to the SEII production medium (20 ml) containing 20 mg/L of streptomycin and cultured at 37°C for 34 hours with shaking. After completion of the culture, the cells were removed by centrifugation, and the concentration of L-lysine contained in the culture supernatant was quantified by using an amino acid analyzer (Nihon Bunko, high-performance liquid chromatography). The results are shown in Table 2. The strains introduced with pRSlysE562dapA or pRSlysE564dapA showed improved L-lysine accumulation. L-lysine accumulation in the media was markedly improved as compared with that introduced solely with pRSlysE562 or pRSlysE564. Thus, it can be seen that the rate limitation for the secretion was eliminated, and the *dapA*^{*} gene enhancing effect was synergistically exhibited.

Table 2

Bacterial strain	L-Lysine production amount (g/L)
AS1/pRS	< 0.10
AS1/pRSlysE562dapA	1.42
AS1/pRSlysE564dapA	1.40

Example 3: Introduction of *lysE564* gene into *Methylobacillus glycogenes* and L-amino acid production

(1) Preparation of pRS-lysE564-Tc

[0121] It was decided to confirm whether *lysE562*, *lysE564* and *lysE565*, which contain mutant *lysE*, function in *Methylobacillus* bacteria. For this purpose, *lysE564* was selected, and pRSlysE564, a plasmid for expression of *lysE564*, was modified. The pRSlysE564 plasmid carries a streptomycin resistant gene. However, since *Methylobacillus glycogenes* is originally resistant to streptomycin, the pRSlysE plasmid cannot be screened. Therefore, a modified plasmid was constructed by inserting a tetracycline resistance gene into the pRSlysE plasmid that could be used in *Methylobacillus glycogenes*.

[0122] First, pRS-lysE564-Tc carrying the tetracycline resistance gene was constructed from pRSlysE564. The pRS-lysE564 plasmid was digested with a restriction enzyme *EcoRI* and added to a phenol/chloroform solution and mixed to terminate the reaction. The reaction mixture was centrifuged, and the upper layer was collected. DNAs were collected by ethanol precipitation, and the digested ends thereof were blunt-ended by using DNA Blunting Kit (Takara Shuzo). DNA fragments were separated on a 0.8% agarose gel, and a DNA fragment having about 9 kilobase pairs (henceforth abbreviated as “kbp”) was collected by using EASY TRAP Ver. 2 (DNA collection kit, Takara Shuzo).

[0123] Furthermore, the tetracycline resistance gene region was amplified by PCR using the pRK310 plasmid (Pansegrau et al., J. Mol. Biol. 239, 623-663 (1994) as a template and the primers shown in SEQ ID NOS: 13 and 14 (a cycle consisting of denaturation at 94°C for 20 seconds, annealing at 55°C for 30 seconds and extension reaction at 72°C for 60 seconds was repeated for 30 cycles). Pyrobest DNA polymerase (Takara Shuzo) was used for PCR. The amplified DNA fragment containing the tetracycline resistance gene region was purified by using PCR prep (Promega), and then DNAs were collected by ethanol precipitation, blunt-ended and phosphorylated by using TaKaRa BKL Kit (Blunting Kination Ligation Kit, Takara Shuzo), added to a phenol/chloroform solution and mixed to terminate the reaction. After the reaction mixture was centrifuged, the upper layer was collected, and DNAs were collected by ethanol precipitation and separated on a 0.8% agarose gel. A DNA fragment of 1.5 kbp was collected by using EASY TRAP Ver. 2.

[0124] The tetracycline resistance gene can also be obtained by a PCR method similar to the above method by using another plasmid, for example, the pRK2 plasmid, as a template instead of pRK310.

[0125] The pRSlysE564 vector fragment prepared as described above and the DNA fragment containing the tetracycline resistance gene region were ligated by using DNA Ligation Kit Ver. 2 (Takara Shuzo). *Escherichia coli* (*E. coli* JM109 competent cells, Takara Shuzo) was transformed with this ligation reaction solution, applied on the LB agar medium containing 20 mg/L of streptomycin and 15 mg/L of tetracycline and cultured overnight at 37°C. The colonies that appeared on the agar medium were inoculated to the LB liquid medium containing 20 mg/L of streptomycin and 15 mg/L of tetracycline and cultured at 37°C for 8 hours with shaking. Plasmid DNA was extracted from each culture broth by the alkaline SDS method, and the structure of each plasmid was confirmed by digestion with restriction enzymes to obtain pRS-lysE564-Tc.

(2) Introduction of pRS-lysE564-Tc into *Methylobacillus* bacterium and L-amino acid production

[0126] pRS-lysE564-Tc obtained as described above was introduced into the *Methylobacillus glycogenes* NCIMB11375 strain by electroporation (Canadian Journal of Microbiology, 43, 197 (1997)). As a control, pRK310 was similarly introduced into the *Methylobacillus glycogenes* NCIMB11375 strain. As a result, colonies containing pRS-lysE564-Tc were obtained at almost the same frequency as those obtained with pRK310, the control.

[0127] pRSlysET was constructed by inserting a tetracycline resistance gene region into the pRSlysE plasmid carrying wild-type *lysE* in the same manner as for pRS-lysE564-Tc, and it was attempted to introduce it into the *Methylobacillus glycogenes* strain in the same manner. However, no strain introduced with it was obtained. This is the same phenomenon observed in the *Methylophilus methylotrophus* AS1 strain, and it was estimated that wild-type *lysE* did not normally function also in *Methylobacillus* bacteria.

[0128] The *Methylobacillus glycogenes* NCIMB11375 strain harboring pRS-lysE564-Tc was applied to an SEII plate containing 10 mg/L of tetracycline and cultured overnight at 30°C. Then, the cells on about 10 cm² of the medium surface were scraped and inoculated to the SEII production medium (20 ml) containing 10 mg/L of tetracycline and cultured at 30°C for 60 hours with shaking. After completion of the culture, the cells were removed by centrifugation, and the concentration of L-lysine contained in the culture supernatant was quantified using an amino acid analyzer (Nihon Bunko, high-performance liquid chromatography). The results are shown in Table 3.

Table 3

Bacterial strain	L-lysine production amount (g/L)
NCIMB11375/pRK310	0.10
NCIMB11375/pRS-lysE564-Tc	1.40

(3) Construction of pRS-lysE564-dapA-Tc

[0129] It was found that L-lysine accumulated in a medium by introducing the *lysE564* gene into the *Methylobacillus glycogenes* strain. It was considered that this was due to the enhancement of L-lysine secretion.

[0130] Accordingly, the effect of enhancement on expression of a L-lysine biosynthesis gene and the *lysE564* gene in combination in *Methylobacillus glycogenes* was examined in the same manner as in Example 2.

[0131] A plasmid was constructed by incorporating the tetracycline resistance gene into the pRSlysE564dapA plasmid prepared in Example 2, (2) by the same method as in Example 3, (1). The obtained plasmid was designated as pRS-lysE564-dapA-Tc.

(4) Introduction of pRS-lysE564-dapA-Tc plasmid into *Methylobacillus glycogenes* and L-amino acid production

[0132] pRS-lysE564-dapA-Tc obtained as described above was introduced into the *Methylobacillus glycogenes* NCIMB11375 strain by electroporation. The L-amino acid concentrations in the culture broth supernatants were examined for the obtained transformant strain (henceforth also referred to as “NCIMB11375/pRS-lysE564-dapA-Tc”), the aforementioned *Methylobacillus glycogenes* strain introduced with pRS-lysE564-Tc (henceforth also referred to as “NCIMB11375/pRS-lysE564-Tc”) and the *Methylobacillus glycogenes* strain introduced with the pRK310 plasmid as a control (henceforth also referred to as “NCIMB11375/pRK310”).

[0133] Each transformant strain was cultured on an SEII plate containing 10 mg/L of tetracycline for two days at 30°C. Then, the cells on 10 cm² of the medium surface were scraped and inoculated to the SEII production medium (20 ml) containing 10 mg/L of tetracycline and cultured at 30°C for 60 hours with shaking. After completion of the culture, the cells were removed from a part of the culture broth by centrifugation, and the concentrations of L-amino acids contained in the culture supernatant were quantified by using an amino acid analyzer.

[0134] The results are shown in Table 4. A marked amount of L-lysine was accumulated in the medium containing the strain introduced with NCIMB11375/pRS-lysE564-dapA-Tc. The L-lysine accumulation in the medium containing the strain introduced with NCIMB11375/pRS-lysE564-dapA-Tc was improved as compared with the case where pRSlysE564T is solely introduced. It was considered that the rate limitation for the secretion was eliminated due to the introduction of the *lysE564* gene, and the *dapA** gene enhancing effect was synergistically exhibited.

Table 4

Bacterial strain	L-lysine concentration in culture supernatant (g/L)
NCIMB11375/pRK310	0.20
NCIMB11375/pRSlysE564T	1.40
NCIMB11375/pRS-lysE564-dapA-Tc	1.62

[0135] While the invention has been described in detail with reference to preferred embodiments thereof, it will be apparent to one skilled in the art that various changes can be made, and equivalents employed, without departing from the scope of the invention. Each of the aforementioned documents is incorporated by reference herein in its entirety, including the foreign priority document, JP2002-336315.

Explanation of Sequence Listing:

SEQ ID NO: 1: Wild-type *lysE* nucleotide sequence

SEQ ID NO: 2: Wild-type LysE amino acid sequence

SEQ ID NO: 3: Wild-type *dapA* nucleotide sequence

SEQ ID NO: 4: Wild-type DDPS amino acid sequence

SEQ ID NOS: 5 and 6: Primers for *lysE*562 site-specific mutation

SEQ ID NOS: 7 and 8: Primers for tac promoter amplification

SEQ ID NOS: 9 and 10: Primers for cloning of *lysE*

SEQ ID NOS: 11 and 12: Primers for cloning of *dapA**

SEQ ID NOS: 13 and 14: Primers for amplification of tetracycline resistance gene region